AU663479B2 - Use of NADH and NADPH as energy substitutes - Google Patents

Use of NADH and NADPH as energy substitutes Download PDF

Info

Publication number
AU663479B2
AU663479B2 AU10392/92A AU1039292A AU663479B2 AU 663479 B2 AU663479 B2 AU 663479B2 AU 10392/92 A AU10392/92 A AU 10392/92A AU 1039292 A AU1039292 A AU 1039292A AU 663479 B2 AU663479 B2 AU 663479B2
Authority
AU
Australia
Prior art keywords
nadh
nadph
nicotinamide
adenine
reduced form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU10392/92A
Other versions
AU1039292A (en
Inventor
Jorg Birkmayer
Walther Birkmayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU1039292A publication Critical patent/AU1039292A/en
Application granted granted Critical
Publication of AU663479B2 publication Critical patent/AU663479B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/153Nucleic acids; Hydrolysis products or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13Nucleic acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Dental Preparations (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Use is described of nicotinamide adenine dinucleotide in its reduced form (NADH) and/or nicotinamide adenine dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically tolerated salt of the same for energy substitution in humans or animals, as is a foodstuff or confectionary product for human consumption or a feedstuff for animal consumption having a content of the substances mentioned.

Description

P/00/011 28/5191 Regulation 3.2(2)
AUSTRALIA
Patents Act 1990 t3 47
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT It C C IC C It 4111 4 Ct ft C II It C I t C C (444 t I C 4 C 4
C
11.49.
C 4 Application Number: Lodged: Invention Title: USE OF NADH AND NADPH AS ENERGY SUBSTITUTES It II I S 4
I
.4 4 S S 0C The following statement is a full description of this invention, including the best method of performing it kinown to k Use of NADH and NADPH as energy substitutes.
The present application relates to a novel use of nicotinamide-adeninedinucleotide in its reduced form (NADH) and/or nicotinamide-adeninedinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, as well as a food or beverage for human consumption or a feed for animal consumption with a content of said substances, For some years now, particularly in the sporting sector, the most varied energy-increasing products have been in favour, either in the form of the largely forbidden anabolics for increasing muscle formation, or the relatively harmless, but largely ineffective products such as sports o- drinks, chocolate bars, etc.
o e The problem of the present invention is to make available products, which act as highly effective and completely harmless energy substitutes in the human or animal body.
According to the invention this problem is solved by the use of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dijicleotide phosphate in its reduced form (NADPH) and/or a physiologically acceptable salt thereof for energy substitution in S the human or animal body. According to a preferred embodiment of the invention said substances are added to a food or drink or to a feed.
S* Alternatively the substances can also be used as the single active ingredient or active ingredient component in a medicamern i improving efficiency and/or for retarding deterioration and/or aging processes. A particularly preferred use of said substances is as or in a geriatric product.
With particular preference NADH and/or NADPH and/or the physiologically accepte.le salt thereof is administered in a quantity which supplies -2the human or animal body with a single dose of 0.01 to 1.0 mg/kg of body weight.
The invention also relates to a food or beverage for human consumption having a content of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleot phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, said substances preferably being contained in a quantity enabling the human body to be supplied with 0.01 to 1.0 mg/kg of body weight of said substances per daily consumption unit.
Finally, the invention relates to a feed for animal consumption having j I a content of nicotinamide-adenine-dinucleotide in its reduced form (NADH) nd/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof, said substances preferably being contained in a quantity such that the animal body is supplied with 0.01 to 1.0 mg/kg of body weight per daily consumption unit.
The "daily consumption unit" is understood to be that quantity of a food or beverage or feed, which is normally consumed every day by a S specific human or animal. As NADH and NADPH are endogenic substances an increase in this quantity in individual cases is not critical, because any overdoses will not have harmful effects on the organism.
The invention is based on the finding that NADH and NADPH, apart from other energy-rich molecules such as adenine triphosphate (ATP), store in the body the energy released by energy-supplying nutrients such as carbohydrates, fats and proteins and make same available to biosynthetic processes.
The most important function of NADH is its driving force for cell respiration. When using oxygen NADH forms water and three ATP molecules in accordance with the following formula: i f 3- NADH H +1/2 0 2 3 Pi 3 ADP- NAD 3 ATP 4H 2 0 Thus, with one NADH molecule three ATP molecules are obtained, which have an energy of in all approximately 21 kilocalories. This process is called oxidative phosphorylation. The quantitative significance of this process for the human body can be demonstrated by a simple mathematical example. A person weighing 70kg requires roughly 2800 kilocalories daily when at rest. This energy quantity can be obtained by the hydrolysis of approximately 384 mole of ATP corresponding to 190 kg of said substance. However, the ATP quantity present in the human body is only 50g. Therefore the organism must produce the remaining 189.95kg every day.
o 0 The supply of NADH or NADPH makes this work much easier for the organism, because it consequently has greater energy reserves. It is also possible to stimulate the many other metabolic reactions catalyzed by the S two coenzymes NADH and NADPH. As ATP plays an important part in regulating the vascular tonus, muscle contraction, in cardiovascular functions, in neurotransmission and in thrombocyte aggregation, which are all central parameters for the well-being and efficiency of humans and animals, an increase in the number of ATP molecules by supplying NADH or NADPH not only leads to an energy substitution, but to an improvement in the general state of health and to a retarding of deterioration and aging processes.
The use of the inventive compounds is completely harmless for the human and animal organism, because they are endogenic substances. Thus, in clinical tests on humans up to 20 times higher concentrations were admini istered than the indicated individual dose maximum in humans in the form of intravenous injections. No side-effects were observed. Research has shown that if the organism is supplied with too much NADH or NADPH, it is immediately oxidized to NAD or NADP and this is a reversible equilibrium reaction.
1 s 4 At present there is no clear picture concerning further possible action mechanisms of NADH or NADPH leading to the further positive effects on the organism described in the following description of cases.
Case Descriptions Case 1: Tennis professional, aged 24, male, was given 5mg of NADH twice weekly in tablet form. After three weeks subjective and objective increase in the body efficiency and physical fitness, reduced fatigue after matches, reduced sleep requirement, increased alertness and attentiveness.
0 00 °o S I Case 2: Manager, aged 49, male, with a fourteen hour working day, was given a chocolate bar containing lOmg of NADPH once weekly. After taking thee times there was a clear increased efficiency, reduced fatigue, able to stop drinking coffee, reduced sleep requirement, increased physical and intellectual activity at the end of the working day.
Case 3: Artist, aged 70, male, uninterested in work, inactive, sleeps until noon, was given twice weekly (for consumption in one day) one litre of a refreshing drink containing 15mg of NADH. After three weeks, *4 active, energy-laden, gets up early, works all day, has a good mood and feels physically and intellectually better. After stopping NADH f f administration for four weeks, a return to the previous state with the.
old complaints. Treatment resumed with tablets containing 5mg of NADPH twice weekly. After one week clear improvement and after fourteen days I restoration of the original active well-being.
Case 4: Six year old racehorse, which had not been successful for a long time and lacking interest in food or movement. Following a six week administration period of feed pellets with a content of 0.5 mg/kg of body weight per daily consumption unit, clear increase in food and movement, much fresher and more active, with a first racing success after ten weeks treatment.
Ii 4 The features disclosed in the description and claims can be essential to the realization of the different embodiments of the invention, either singly or in the form of random combinations.
I 4 4 14 4494 a ft I 4, L4 ~3 4 4 4 It; I 9 4.4; 4 4 4 It 4 a A:
(C
44 44 44 1 a
I

Claims (5)

1. Use of one or more compounds from the group consisting of nicotinamide-adenine-dinucleotide in its reduced form (NADH), nicotinamide- adenine-dinucleotide phosphate in its reduced form (NADPH), and a physiologically compatible salt of NADH or NADPH for energy substitution in the human and animal body.
2. Use according to claim 1 as an additive to a food or drink.
3. Use according to claim 1 as an additive to a feed. Use according to one of the claims 2 to 4, characterized in that the one or more compounds is administered in a quantity giving the animal or human body a total single dose of 0.01 to 1.0 mg/kg of body weight.
6. Food or beverage used for energy substitution and for human consumption with a content of one or more compounds from the group consisting of nicotinamide-adenine-dinucleotide in its reduced form (NADH), nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and a physiologically compatible salt of NADH or NADPH as a food additive in adjunct with edible, non-toxic carriers and excipients. I 7
7. Feed for animal consumption used for energy substitution and with a content of one or more compounds from the group consisting of nicotinamide- adenine-dinucleotide in its reduced form (NADH), nicotinamide-adenine- dinucleotide phosphate in its reduced form (NADPH) and a physiologically compatible salt of NADH or NADPH as a food additive in adjunct with edible, non-toxic carriers and excipients. DATED this 2nd day of August, 1995 JORG BIRKMAYER I rt r S" WATERMARK PATENT TRADEMARK ATTORNEYS 290 BURWOOD ROAD S" HAWTHORN VICTORIA 3122 AUSTRALIA tL I t I V -8- ABSTRACT Use of nicotinamide-adenine-dinucleotide in its reduced form (NADH) and/or nicotinamide-adenine-dinucleotide phosphate in its reduced form (NADPH) and/or a physiologically compatible salt thereof for energy substitution in the human or animal body, as well as a food or drink for human consumption or a feed for animal consumption having a content of said substances. a 1 3 I i C it ti II I j0 I I_-
AU10392/92A 1991-01-24 1992-01-23 Use of NADH and NADPH as energy substitutes Ceased AU663479B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4102240 1991-01-24
DE4102240A DE4102240C1 (en) 1991-01-24 1991-01-24

Publications (2)

Publication Number Publication Date
AU1039292A AU1039292A (en) 1992-07-30
AU663479B2 true AU663479B2 (en) 1995-10-12

Family

ID=6423720

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10392/92A Ceased AU663479B2 (en) 1991-01-24 1992-01-23 Use of NADH and NADPH as energy substitutes

Country Status (14)

Country Link
EP (1) EP0496479B1 (en)
JP (1) JP2533709B2 (en)
AT (1) ATE112664T1 (en)
AU (1) AU663479B2 (en)
BR (1) BR9200207A (en)
CA (1) CA2059510C (en)
DE (2) DE4102240C1 (en)
DK (1) DK0496479T3 (en)
ES (1) ES2061313T3 (en)
FI (1) FI920323A (en)
HU (1) HU9200213D0 (en)
IE (1) IE69861B1 (en)
NO (1) NO304672B1 (en)
ZA (1) ZA92275B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2167104A1 (en) * 1995-01-17 1996-07-18 Joerg G.D. Birkmayer Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
IT1318565B1 (en) * 2000-06-09 2003-08-27 World Pharma Tech Ltd NADH OCTOCOSANOL EVITAMIN E PROENERGETIC FOOD SUPPLEMENT
US20040126751A1 (en) * 2002-12-27 2004-07-01 Birkmayer Jorg G.D. Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose
DE102008010245B4 (en) * 2008-02-20 2011-02-10 Emag Holding Gmbh Method for grinding wavy workpieces
DE102014103443A1 (en) * 2014-03-13 2015-09-17 Jürgen Ruhlmann Composition for use in the treatment of fatigue, lack of concentration, withdrawal symptoms, headaches and colds, in particular loss of power, hangover and fatigue
WO2020021734A1 (en) * 2018-07-26 2020-01-30 オリジンバイオテクノロジー株式会社 Functional chicken eggs and method for producing same
DE202022000567U1 (en) 2022-03-06 2022-03-16 Penta Phi Eg Liposomal formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594475A (en) * 1968-04-24 1971-07-20 Kyowa Hakko Kogyo Kk Method of treating and preventing the side effects of antibiotics
EP0107161B1 (en) * 1982-10-26 1989-08-09 CTA Finanz AG Device and process for optimising the tissue mass of organs within the genetic fluctuation range in humans and animals
IT1162938B (en) * 1983-08-26 1987-04-01 Dino Spisni COMPOSITION FOR THE TREATMENT OF MALIGNANT CANCERS, IN PARTICULAR ON ANIMALS
JPS60126220A (en) * 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc Nucleic acid component composition
ES2007350A6 (en) * 1987-05-29 1989-06-16 Ganadera Union Ind Agro Food products enriched with nucleosides and/or nucleotides and preparation thereof.
DE58905201D1 (en) * 1988-03-01 1993-09-16 Birkmayer Walther AGENT FOR TREATING THE PARKINSON SYNDROME.
AT397201B (en) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr USE OF THE ENZYME COFACTOR NADPH IN THE PRODUCTION OF A MEDICINAL PRODUCT

Also Published As

Publication number Publication date
JP2533709B2 (en) 1996-09-11
ATE112664T1 (en) 1994-10-15
NO304672B1 (en) 1999-02-01
ZA92275B (en) 1992-12-30
IE69861B1 (en) 1996-10-16
NO920315D0 (en) 1992-01-23
IE920198A1 (en) 1992-07-29
JPH05262652A (en) 1993-10-12
ES2061313T3 (en) 1994-12-01
EP0496479A1 (en) 1992-07-29
DE4102240C1 (en) 1992-04-09
HU9200213D0 (en) 1992-04-28
AU1039292A (en) 1992-07-30
CA2059510C (en) 1997-06-10
DK0496479T3 (en) 1995-04-18
CA2059510A1 (en) 1992-07-25
FI920323A (en) 1992-07-25
EP0496479B1 (en) 1994-10-12
FI920323A0 (en) 1992-01-24
DE59200603D1 (en) 1994-11-17
NO920315L (en) 1992-07-27
BR9200207A (en) 1992-10-06

Similar Documents

Publication Publication Date Title
Murphy et al. Regular induction of hypomania by L-dopa in “bipolar” manic-depressive patients
Young Growth and diabetes in normal animals treated with pituitary (anterior lobe) diabetogenic extract
Westerfeld et al. Metabolism and caloric value of alcohol
USRE43029E1 (en) Process for preparing a creatine heterocyclic acid salt and method of use
JP5714227B2 (en) Anti-fatigue agent and oral composition containing andrographolide as active ingredient
EP1252892A1 (en) Composition for reducing mental fatigue, composition for maintaining and enhancing concentration, and composition for maintaining and enhancing mental vigor
CN1272790A (en) Method for promoting weight and fat loss with composition comprising hydroxycitrate, carnitine and pyruvate promotor
CN102448452A (en) Dietary supplement comprising alpha keto acids for supporting diabetes therapy
JP6629595B2 (en) Synergistic dietary supplement composition for enhancing physical performance and energy levels
US20050249713A1 (en) Dietary supplement energy-providing to skeletal muscles and protecting the cardiovascular tract
AU663479B2 (en) Use of NADH and NADPH as energy substitutes
CN102273581A (en) Compound sweetener with high sweetness
US20010020007A1 (en) Vitamin preparations for reducing oxygen consumption during physical efforts
Littman et al. Acceleration of growth of sarcoma 180 with pyridoxamine and retardation with penicillamine.
Gibala Dietary protein, amino acid supplements, and recovery from exercise
JPH0995448A (en) Increase in biotin concentration in blood and biotin-containing beverage or food product
US6703371B1 (en) Preparations for reducing oxygen consumption during physical efforts
Elvehjem The Biological Significance of Nicotinic Acid: Harvey Lecture, November 16, 1939
EP2042170B1 (en) Creatine composition and use
US20230025468A1 (en) Method and a dietary composition on regulation, treatment, and prevention of obesity
Burke Branched-chain amino acids (BCAAs) and athletic performance
EP0920321A1 (en) Vitamine preparations for reducing oxygen consumption during physical efforts
UA127073C2 (en) HERODIETICAL MIXTURE FOR ENTERAL NUTRITION FOR PERSONS WITH DIABETES DISEASE
JPWO2014163151A1 (en) Yeast culture and oral composition
CZ5849U1 (en) Special natural stimulant of organism

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired